logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Agenus Inc.


USPTO Granted Patents = 53

% Expired Patents = 9.4



Trademarks = 2

Forward Citations = 123

Loading Chart...
Loading Chart...

65 inventors (with patents filed for the assignee):

goldMedal Marc A Van Dijk (36 out of 42 patents)

silverMedal Nicholas Stuart Wilson (34 out of 37 patents)

bronzeMedal Taha Merghoub (26 out of 45 patents)

4.  David Schaer (26 out of 27 patents)

5.  Gerd J Ritter (26 out of 61 patents)

6.  David Adam Savitsky (22 out of 24 patents)

7.  Cornelia Anne Mundt (17 out of 21 patents)

8.  Dennis John Underwood (17 out of 30 patents)

9.  Jedd David Wolchok (14 out of 37 patents)

10.  Volker Seibert (12 out of 14 patents)

11.  Ekaterina Vladimirovna Breous-Nystrom (12 out of 14 patents)

12.  Jeremy Dale Waight (11 out of 11 patents)

13.  Olivier Léger (9 out of 9 patents)

14.  Takemasa Tsuji (9 out of 14 patents)

15.  Daniel Hirschhorn-Cymerman (8 out of 8 patents)


Core Competencies:
Anti-TIGIT
Anti-CTLA-4
Anti-PD-1
Anti-GITR
Anti-LAG-3
Antigen-Binding Fragments
Cancer Vaccines
MHC Class I
Nucleic Acids
Protein Production
Heat Shock Proteins
SHLA Technology

53 patents:

1. 12630628 - ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF (2026-05-19),
2. 12344670 - Anti-ILT4 antibodies and antigen-binding fragments (2025-07-01),
3. 12246066 - Anti-CTLA-4 antibodies and methods of use thereof (2025-03-11),
4. 12187795 - Anti-LAG-3 antibodies and methods of use thereof (2025-01-07),
5. 12011481 - Anti-TIM-3 antibodies and methods of use thereof (2024-06-18),
6. 11993653 - Antibodies and methods of use thereof (2024-05-28),
7. 11993651 - Anti-lag-3 antibodies and methods of use thereof (2024-05-28),
8. 11897962 - Anti-GITR antibodies and methods of use thereof (2024-02-13),
9. 11897957 - Anti-ILT4 antibodies and antigen-binding fragments (2024-02-13),
10. 11897956 - Anti-ILT4 antibodies and antigen-binding fragments (2024-02-13),
11. 11839653 - Anti-TIM-3 antibodies and methods of use thereof (2023-12-12),
12. 11718669 - Anti-TIGIT and anti-CD96 antibodies (2023-08-08),
13. 11692042 - Anti-CD73 antibodies and methods of use thereof (2023-07-04),
14. 11680098 - Antibodies that specifically bind human CD96 (2023-06-20),
15. 11638755 - Anti-CTLA-4 antibodies and methods of use thereof (2023-05-02),
Agenus Inc., headquartered in Lexington, MA, specializes in the development of innovative immuno-oncology therapies, particularly monoclonal antibodies. The company focuses on advancing treatments targeting critical immune checkpoints such as TIGIT, CTLA-4, PD-1, GITR, and LAG-3, alongside antigen-binding fragments and cancer vaccines. With a commitment to enhancing cancer treatment options, Agenus is at the forefront of research aimed at harnessing the immune system to combat various cancers.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Agenus Inc.
53 Patents

#18 in Lexington, MA

#377 in Massachusetts

#6,661 in US

#13,309 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Agenus Inc.

Forward Citations = 123

65 inventors:

goldMedal Marc A Van Dijk (36 out of 42 patents)

silverMedal Nicholas Stuart Wilson (34 out of 37 patents)

bronzeMedal Taha Merghoub (26 out of 45 patents)

4.  David Schaer (26 out of 27 patents)

5.  Gerd J Ritter (26 out of 61 patents)

Please report any incorrect information to [email protected]
Loading…